We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The latest approval is based on data from a phase 3 trial in which Liletta was about 99 percent effective in preventing pregnancy up to eight years. Read More
The approval was based on a clinical trial in which about 35 percent of the 106 enrolled ovarian cancer patients were positive for the marker, as determined by the assay. Read More
Roche’s Ventana FOLR1 assay has been approved by the FDA as the first companion diagnostic test to identify patients eligible for treatment with ImmunoGen’s Elahere (mirvetuximab soravtansine-gynx) also recently FDA approved. Read More